July 13, 2020

The Niche

Knoepfler lab stem cell blog

patient adverse events

5 min read

Stem cells for MS? How promising is that? A new paper gives stronger reason for hope, but unfortunately this story is more complex than it seems on first glance. New Paper The idea of using a stem cell-related approach to treat multiple sclerosis (MS) has been around for a long time holding major promise, but there hasn’t been much in the way of high-quality trial data out there in the published literature. A paper this week from the Richard Burt team at Northwestern (NW) …Read More

2 min read

E. coli is a type of bacteria that can cause diseases such as serious GI illness if it ends up in the wrong place like in your food. You can spend the night in the bathroom or end up in the hospital or more rarely a grave depending on the subtype of E. coli. Some are harmless or maybe beneficial. You can imagine that if pathogenic E. coli or similar bacteria are present in a drug product (which can include stem cells) that is …Read More

3 min read

You probably remember Liveyon. It’s a marketer of an “umbilical cord stem cell” product that was recently recalled by the FDA. The recall was due to adverse events that may have included E. coli contamination somewhere before it was injected into patients, some of whom apparently got sick. Since it seemed like this recalled product was a major part of Liveyon’s business model, some wondered: could the company survive the recall? My sense at the time was that it would just find another source for …Read More

3 min read

The FDA has issued a recall of the main stem cell product of a California firm called Liveyon that is linked to unproven stem cell clinics. The recall seems to have been due to “adverse reactions.” An emerging big player in the birth-related stem cell clinic area? I’ve been hearing the name Liveyon pop up more often in the unproven stem cell clinic industry recently. More specifically, they seem to be a supplier and marketer of birth-related products to clinics. The clinics then in …Read More